Evidence map›Paper›PMID 41878179›Full record

ReviewCureus2026

Freeform vs. Aspheric Spectacle Lenses: A Comprehensive Review of Optical Performance, Clinical Outcomes, and Patient Considerations.

Konstantinos Ladopoulos, Evangelos Pateras, Georgios Ninos

Abstract readReview
In one paragraph

Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Konstantinos LadopoulosBiomedical Sciences, Sector of Optics and Optometry, Laboratory of Optical Metrology, University of West Attica, Athens, GRC.
Evangelos PaterasOptics and Optometry, University of West Attica, Athens, GRC.
Georgios NinosBiomedical Sciences, Sector of Optics and Optometry, Laboratory of Optical Metrology, University of West Attica, Athens, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spectacle lens design has evolved from spherical lenses to aspheric lenses (ASL) and freeform lenses (FFL) to improve peripheral optics and wearer comfort. In this review, we compare ASLs and FFLs across optical performance, visual function, patient-reported outcomes, and practical considerations. We synthesized evidence from more than 90 peer-reviewed studies, technical reports, and authoritative textbooks. Databases included PubMed, Scopus, Web of Science, and specialist optometry sources. Eligibility focused on comparative ASL vs. FFL studies and high-quality reports. Data were organized into themes (optical performance, visual function, subjective outcomes, and practical issues). Both ASLs and FFLs outperform spherical lenses centrally; however, FFLs demonstrate consistently lower peripheral astigmatism and mean power error, wider usable fields of view (particularly in progressive addition lenses (PALs)), and better contrast sensitivity in mesopic/low-contrast conditions. Personalization of position-of-wear parameters (vertex distance, pantoscopic tilt, wrap) is key to FFL advantages. Adaptation appears faster, and patient satisfaction is higher with FFLs, especially in complex prescriptions and progressive designs. The ASLs are cost-effective for moderate prescriptions and standard fits, while FFLs represent the benchmark for personalized spectacle correction, particularly for high ametropia and PALs, provided there are accurate measurements and quality-controlled manufacturing.

Indexed as

aspheric lensescontrast sensitivityfreeform lensespatient’s satisfactionperipheral aberrationsprogressive addition lensesspectacle lens designvisual acuity

Identifiers

PMID41878179
PMCPMC13006856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.